SOLICITATION NOTICE
B -- Circulating Inflammatory Markers of Diagnosis and Prognosis in Lung Cancer in African Americans
- Notice Date
- 11/14/2014
- Notice Type
- Presolicitation
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bldg 1050, Frederick, Maryland, 21702, United States
- ZIP Code
- 21702
- Solicitation Number
- N02RC52507-57
- Point of Contact
- Reyes Rodriguez, Phone: 240-276-5442, Seena Ninan, Phone: 240-276-5419
- E-Mail Address
-
reyes.rodriguez@nih.gov, ninans@mail.nih.gov
(reyes.rodriguez@nih.gov, ninans@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Laboratory of Human Carcinogenesis (LHC), plans to procure on a sole source basis 25 plates of the 30 Plex V plex inflammatory panel from MesoScale Discovery 1601 Research Blvd, Rockville, MD 20850. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). The North American Industry Classification System code is 325414 and the employees size standard is 500. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Delivery of supplies shall be made no later than thirty (30) days after contract award. It has been determined there are no opportunities to acquire green products or services for this procurement. The primary hypotheses of Laboratory of Human Carcinogenesis' (LHC) study on circulating plasma cytokines are: a) circumvent over-diagnosis and potentially contribute to an low-dose CT (LDCT) diagnostic algorithm by better differentiating between benign and malignant nodules; and b) predict the outcome of patients diagnosed with a lung cancer using LDCT. Screening with LDCT will by its nature lead to the detection of more stage I cancers. The latter is a group of patients where there is a particular need for good biomarkers of outcome, as although surgery alone is the standard of care, up to 30% of these patients will experience a recurrence. By annotating which patients will have a poor prognosis, biomarkers that can predict outcome in patients with LDCT-detected cancers will also be advantageous to screening programs and could potentially aid in the selection of downstream therapeutic protocols. LHC has previously shown that circulating cytokines are predictive of lung cancer risk up to 5 years before a diagnosis in European Americans, but LHC has yet to test this hypothesis in African Americans. The literature suggests that this is necessary to do as cytokine profiles, even among controls, are significantly different from European Americans. As cytokines are secreted directly from tumor cells, these data suggest that cytokines will be useful as tools to avoid over-diagnosis of lung cancer detected by LDCT and guiding therapy choices for patients with lung cancer. Contractor Technical requirements: The contractor shall provide: 1) 25 plates of the Human Cytokine 30-Plex V-Plex inflammatory panel 2) 25 Plates for Human CRP Kit 3) Shipping must be included on total pricing In the past, the Laboratory of Human Carcinogenesis (LHC) has conducted studies using this same technology on European Americans and a pilot study of African Americans. If LHC select a different vendor for this study, program will not be able to compare the findings from both studies and this would thus lead to both a missed opportunity for value added research, and the inability to perform one of LHC's objectives, which is to compare signals from European Americans and African Americans. Therefore, using a vendor other than Mesoscale Discovery will be most costly to the Government. This notice is not a request for competitive quotation. However, if any interested party, especially small business believes it can meet the above requirement, it may submit a proposal or quote for the Government to consider. The response and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 11 AM EST, on November 28, 2014. All responses and questions must be in writing and faxed to 240-276-5399 or emailed to Reyes Rodriguez, Contracting Specialist via electronic mail at reyes.rodriguez@nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractors must be registered and have valid certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA) through sam.gov. Reference: N02RC52507-57 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/FCRF/N02RC52507-57/listing.html)
- Place of Performance
- Address: TBD, United States
- Record
- SN03573697-W 20141116/141114234651-a9d6d623da862488a3693e463c89dcee (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |